Document
Table of Contents

 
UNITED STATES
SECURITIES AND EXCHANGE COMMISSION
Washington, D.C. 20549
 
FORM 10-Q
 
ý      QUARTERLY REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934
 
FOR THE QUARTERLY PERIOD ENDED June 30, 2017
 
OR
 
o         TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934
 
FOR THE TRANSITION PERIOD FROM ___________ TO___________
 
Commission file number 1-16671
 
AMERISOURCEBERGEN CORPORATION
(Exact name of registrant as specified in its charter)
Delaware
 
23-3079390
(State or other jurisdiction of
 
(I.R.S. Employer
incorporation or organization)
 
Identification No.)
 
 
 
1300 Morris Drive, Chesterbrook, PA
 
19087-5594
(Address of principal executive offices)
 
(Zip Code)
 (610) 727-7000
(Registrant’s telephone number, including area code)
 
Indicate by check mark whether the registrant (1) has filed all reports required to be filed by Section 13 or 15(d) of the Securities Exchange Act of 1934 during the preceding 12 months (or for such shorter period that the registrant was required to file such reports), and (2) has been subject to such filing requirements for the past 90 days. Yes  ý  No  o
 
Indicate by check mark whether the registrant has submitted electronically and posted on its corporate Web site, if any, every Interactive Data File required to be submitted and posted pursuant to Rule 405 of Regulation S-T during the preceding 12 months (or for such shorter period that the registrant was required to submit and post such files). Yes  ý  No o
 
Indicate by check mark whether the registrant is a large accelerated filer, an accelerated filer, a non-accelerated filer, or a smaller reporting company (as defined in Rule 12b-2 of the Exchange Act).
 
Large accelerated filer ý  Accelerated filer o  Non-accelerated filer o  Smaller reporting company o
 
Indicate by check mark whether the registrant is a shell company (as defined in Rule 12b-2 of the Exchange Act). Yes o   No  ý
 
The number of shares of common stock of AmerisourceBergen Corporation outstanding as of July 31, 2017 was 219,111,565.
 



Table of Contents

AMERISOURCEBERGEN CORPORATION
 
TABLE OF CONTENTS
 
 
Page No.
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 


1

Table of Contents

PART I. FINANCIAL INFORMATION 
ITEM I. Financial Statements (Unaudited)
 
AMERISOURCEBERGEN CORPORATION AND SUBSIDIARIES 
CONSOLIDATED BALANCE SHEETS 
(in thousands, except share and per share data)
 
June 30,
2017
 
September 30,
2016
 
 
(Unaudited)
 
 
ASSETS
 
 

 
 

Current assets:
 
 

 
 

Cash and cash equivalents
 
$
1,311,467

 
$
2,741,832

Accounts receivable, less allowances for returns and doubtful accounts:
$938,446 at June 30, 2017 and $905,345 at September 30, 2016
 
10,553,258

 
9,175,876

Merchandise inventories
 
11,669,529

 
10,723,920

Prepaid expenses and other
 
142,970

 
210,219

Total current assets
 
23,677,224

 
22,851,847

 
 
 
 
 
Property and equipment, at cost:
 
 

 
 

Land
 
40,292

 
40,290

Buildings and improvements
 
994,422

 
859,148

Machinery, equipment, and other
 
1,974,384

 
1,717,298

Total property and equipment
 
3,009,098

 
2,616,736

Less accumulated depreciation
 
(1,259,184
)
 
(1,086,054
)
Property and equipment, net
 
1,749,914

 
1,530,682

 
 
 
 
 
Goodwill
 
6,042,552

 
5,991,497

Other intangible assets
 
2,871,426

 
2,967,849

Other assets
 
312,894

 
295,626

 
 
 
 
 
TOTAL ASSETS
 
$
34,654,010

 
$
33,637,501

 
 
 
 
 
LIABILITIES AND STOCKHOLDERS’ EQUITY
 
 

 
 

 
 
 
 
 
Current liabilities:
 
 

 
 

Accounts payable
 
$
24,804,544

 
$
23,926,320

Accrued expenses and other
 
942,413

 
743,839

Short-term debt
 
4,119

 
610,210

Total current liabilities
 
25,751,076

 
25,280,369

 
 
 
 
 
Long-term debt
 
3,429,074

 
3,576,493

Long-term financing obligation
 
352,719

 
275,991

Deferred income taxes
 
2,400,467

 
2,214,774

Other liabilities
 
167,160

 
160,470

 
 
 
 
 
Stockholders’ equity:
 
 
 
 

Common stock, $0.01 par value - authorized, issued, and outstanding:
600,000,000 shares, 280,371,836 shares, and 219,035,799 shares at June 30, 2017, respectively, and 600,000,000 shares, 277,753,762 shares, and 220,050,502 shares at September 30, 2016, respectively
 
2,804

 
2,778

Additional paid-in capital
 
4,498,536

 
4,333,001

Retained earnings
 
2,819,907

 
2,303,941

Accumulated other comprehensive loss
 
(112,458
)
 
(114,308
)
Treasury stock, at cost: 61,336,037 shares at June 30, 2017 and 57,703,260 shares at September 30, 2016
 
(4,655,275
)
 
(4,396,008
)
Total stockholders’ equity
 
2,553,514

 
2,129,404

 
 
 
 
 
TOTAL LIABILITIES AND STOCKHOLDERS’ EQUITY
 
$
34,654,010

 
$
33,637,501

 See notes to consolidated financial statements.

2

Table of Contents

AMERISOURCEBERGEN CORPORATION AND SUBSIDIARIES
CONSOLIDATED STATEMENTS OF OPERATIONS
(Unaudited)
 
 
Three months ended
June 30,
 
Nine months ended
June 30,
(in thousands, except per share data)
 
2017
 
2016
 
2017
 
2016
 
 
 
 
(As Revised)
 
 
 
(As Revised)
Revenue
 
$
38,707,144

 
$
36,881,680

 
$
114,023,811

 
$
109,289,083

Cost of goods sold
 
37,627,269

 
35,773,817

 
110,649,829

 
106,141,012

Gross profit
 
1,079,875

 
1,107,863

 
3,373,982

 
3,148,071

Operating expenses:
 


 
 

 
 

 
 

Distribution, selling, and administrative
 
525,463

 
516,438

 
1,567,853

 
1,560,981

Depreciation
 
59,478

 
54,000

 
173,083

 
157,861

Amortization
 
40,041

 
40,268

 
120,185

 
112,205

Warrants
 

 
(83,704
)
 

 
(120,275
)
Employee severance, litigation, and other
 
284,517

 
52,234

 
317,517

 
88,719

Pension settlement
 

 

 

 
47,607

Operating income
 
170,376

 
528,627

 
1,195,344

 
1,300,973

Other loss (income)
 
1,398

 
(2,158
)
 
(3,958
)
 
(3,224
)
Interest expense, net
 
35,603

 
35,153

 
109,874

 
104,860

Income before income taxes
 
133,375

 
495,632

 
1,089,428

 
1,199,337

Income tax expense (benefit)
 
83,023

 
146,477

 
380,357

 
(82,907
)
Net income
 
$
50,352

 
$
349,155

 
$
709,071

 
$
1,282,244

 
 
 
 
 
 
 
 
 
Earnings per share:
 
 

 
 

 
 

 
 

Basic
 
$
0.23

 
$
1.62

 
$
3.25

 
$
6.11

Diluted
 
$
0.23

 
$
1.55

 
$
3.20

 
$
5.68

 
 
 
 
 
 
 
 
 
Weighted average common shares outstanding:
 
 

 
 

 
 

 
 

Basic
 
218,676

 
215,688

 
218,336

 
209,898

Diluted
 
221,873

 
224,802

 
221,698

 
225,646

 
 
 
 
 
 
 
 
 
Cash dividends declared per share of common stock
 
$
0.365

 
$
0.340

 
$
1.095

 
$
1.020

 See notes to consolidated financial statements.


3

Table of Contents

AMERISOURCEBERGEN CORPORATION AND SUBSIDIARIES
 CONSOLIDATED STATEMENTS OF COMPREHENSIVE INCOME
(Unaudited) 
 
 
Three months ended
June 30,
 
Nine months ended
June 30,
(in thousands)
 
2017
 
2016
 
2017
 
2016
 
 
 
 
(As Revised)
 
 
 
(As Revised)
Net income
 
$
50,352

 
$
349,155

 
$
709,071

 
$
1,282,244

Other comprehensive income (loss)
 


 


 


 


Net change in foreign currency translation adjustments
 
10,841

 
(8,911
)
 
1,829

 
(5,434
)
Pension plan adjustment, net of tax of $19,054
 

 

 

 
31,538

Other
 
191

 
117

 
21

 
(749
)
Total other comprehensive income (loss)
 
11,032

 
(8,794
)
 
1,850

 
25,355

Total comprehensive income
 
$
61,384

 
$
340,361

 
$
710,921

 
$
1,307,599

See notes to consolidated financial statements.


4

Table of Contents

AMERISOURCEBERGEN CORPORATION AND SUBSIDIARIES 
CONSOLIDATED STATEMENTS OF CASH FLOWS
(Unaudited)
 

Nine months ended
June 30,
(in thousands)

2017

2016
OPERATING ACTIVITIES

 


(As Revised)
Net income

$
709,071


$
1,282,244

Adjustments to reconcile net income to net cash provided by operating activities:






Depreciation, including amounts charged to cost of goods sold

192,865


171,753

Amortization, including amounts charged to interest expense

127,395


116,961

Provision for doubtful accounts

8,651


11,310

Provision (benefit) for deferred income taxes

225,948


(220,739
)
Warrants income



(120,275
)
Share-based compensation

51,592


56,561

LIFO (credit) expense
 
(82,919
)
 
274,305

Pension settlement


 
47,607

Other

(767
)

(6,446
)
Changes in operating assets and liabilities, excluding the effects of acquisitions and divestitures:






Accounts receivable

(1,419,099
)

(705,462
)
Merchandise inventories

(829,903
)

(949,887
)
Prepaid expenses and other assets

23,844


35,270

Accounts payable

876,977


1,776,565

Accrued expenses, income taxes, and other liabilities

240,029


54,209

NET CASH PROVIDED BY OPERATING ACTIVITIES

123,684


1,823,976

INVESTING ACTIVITIES

 


 

Capital expenditures

(371,428
)

(310,178
)
Cost of acquired companies, net of cash acquired

(61,633
)

(2,731,356
)
Cost of equity investments
 
(8,300
)
 
(19,034
)
Proceeds from sales of investment securities available-for-sale

70,008


101,829

Purchases of investment securities available-for-sale

(48,635
)

(41,136
)
Other

13,422


(21,186
)
NET CASH USED IN INVESTING ACTIVITIES

(406,566
)

(3,021,061
)
FINANCING ACTIVITIES

 


 

Term loan borrowings



1,000,000

Senior notes and term loans repayments
 
(750,000
)
 
(600,000
)
Borrowings under revolving and securitization credit facilities

6,784,159


8,788,432

Repayments under revolving and securitization credit facilities

(6,791,411
)

(8,273,610
)
Purchases of common stock

(229,928
)

(1,023,149
)
Exercises of warrants
 

 
1,168,891

Exercises of stock options, including excess tax benefits of $21,853 in fiscal 2016

94,325


73,356

Cash dividends on common stock

(240,168
)

(215,070
)
Tax withholdings related to restricted share vesting
 
(9,339
)
 
(18,935
)
Other

(5,121
)

(5,070
)
NET CASH (USED IN) PROVIDED BY FINANCING ACTIVITIES

(1,147,483
)

894,845

DECREASE IN CASH AND CASH EQUIVALENTS

(1,430,365
)

(302,240
)
Cash and cash equivalents at beginning of period

2,741,832


2,167,442

CASH AND CASH EQUIVALENTS AT END OF PERIOD

$
1,311,467


$
1,865,202

 See notes to consolidated financial statements.

5

Table of Contents

AMERISOURCEBERGEN CORPORATION AND SUBSIDIARIES
NOTES TO CONSOLIDATED FINANCIAL STATEMENTS
(Unaudited)
 
Note 1.  Summary of Significant Accounting Policies
 
Basis of Presentation
 
The accompanying financial statements present the consolidated financial position, results of operations, and cash flows of AmerisourceBergen Corporation and its wholly-owned subsidiaries (the "Company") as of the dates and for the periods indicated.  All intercompany accounts and transactions have been eliminated in consolidation.
 
The accompanying unaudited consolidated financial statements have been prepared in conformity with U.S. generally accepted accounting principles ("GAAP") for interim financial information, the instructions to Form 10-Q, and Rule 10-01 of Regulation S-X. In the opinion of management, all adjustments (consisting only of normal recurring accruals, except as otherwise disclosed herein) considered necessary to present fairly the financial position as of June 30, 2017 and the results of operations and cash flows for the interim periods ended June 30, 2017 and 2016 have been included. Certain information and footnote disclosures normally included in financial statements presented in accordance with U.S. GAAP, but which are not required for interim reporting purposes, have been omitted. The accompanying unaudited consolidated financial statements should be read in conjunction with the financial statements and notes thereto included in the Company’s Annual Report on Form 10-K for the fiscal year ended September 30, 2016.
 
The preparation of financial statements in conformity with U.S. GAAP requires management to make estimates and assumptions that affect amounts reported in the financial statements and accompanying notes. Actual amounts could differ from these estimated amounts. Certain reclassifications have been made to prior-period amounts in order to conform to the current year presentation.
Recently Adopted Accounting Pronouncements
In April 2015, the FASB issued ASU No. 2015-03, "Interest - Imputation of Interest (Subtopic 835-30): Simplifying the Presentation of Debt Issuance Costs" ("ASU 2015-03"). ASU 2015-03 specifies that debt issuance costs related to a debt liability shall be reported on the balance sheet as a direct reduction from the face amount of the debt liability. In August 2015, the FASB issued ASU No. 2015-15, "Interest - Imputation of Interest (Subtopic 835-30): Presentation and Subsequent Measurement of Debt Issuance Costs Associated with Line-of-Credit Arrangements" ("ASU 2015-15"). ASU 2015-15 specifies that debt issuance costs related to line-of-credit arrangements may be presented as an asset on the balance sheet and subsequently amortized ratably over the term of the line-of-credit arrangement, regardless of whether there are any outstanding borrowings on the line-of-credit arrangement. As of October 1, 2016, the Company adopted ASU 2015-03 and ASU 2015-15 on a retrospective basis, which resulted in the reclassification of $18.7 million of debt issuance costs from Other Assets to Short-Term Debt of $0.9 million and to Long-Term Debt of $17.8 million on the Company's September 30, 2016 Consolidated Balance Sheet. The adoption had no impact on the Company’s results of operations or cash flows.
In March 2016, the FASB issued ASU No. 2016-09, "Compensation — Stock Compensation (Topic 718): Improvements to Employee Share-Based Payment Accounting" ("ASU 2016-09"). ASU 2016-09 requires all income tax effects of awards to be recognized in the income statement when the awards vest or are settled. It also allows an employer to repurchase more of an employee's shares than it may currently for tax withholding purposes without triggering liability accounting and to make a policy election to account for forfeitures as they occur. ASU 2016-09 is effective for annual reporting periods beginning after December 15, 2016 and interim periods within those fiscal years. Entities are permitted to adopt the standard early in any interim or annual period. During the quarter ended December 31, 2016, the Company early adopted ASU 2016-09, which resulted in a cumulative adjustment to retained earnings and established a deferred tax asset as of October 1, 2016 of $47.1 million for previously unrecognized tax benefits. The Company elected to adopt the Statement of Cash Flows presentation of the excess tax benefits prospectively. During the three and nine months ended June 30, 2017, the Company recognized tax benefits of $10.0 million and $34.0 million, respectively, in Income Tax Expense on the Company's Consolidated Statement of Operations. The tax benefits recognized in the three and nine months ended June 30, 2017 are not necessarily indicative of amounts that may arise in future periods.
Recently Issued Accounting Pronouncements Not Yet Adopted
In May 2014, the FASB issued ASU No. 2014-09, "Revenue from Contracts with Customers (Topic 606)" ("ASU 2014-09"). ASU 2014-09 supersedes the revenue recognition requirements in Accounting Standards Codification 605 — "Revenue Recognition" and most industry-specific guidance throughout the Codification. ASU 2014-09 outlines a single comprehensive model for entities to use in accounting for revenue arising from contracts with customers. The standard's core principle is that a company should recognize revenue to depict the transfer of promised goods or services to customers in an amount that reflects

6


the consideration to which the entity expects to be entitled in exchange for those goods or services. ASU 2014-09 was originally scheduled to be effective for annual reporting periods beginning after December 15, 2016, including interim periods within those reporting periods. In July 2015, the Financial Accounting Standards Board deferred the effective date of ASU 2014-09 by one year.
In March 2016, the FASB issued ASU No. 2016-08, "Revenue from Contracts with Customers (Topic 606) — Principal versus Agent Considerations" ("ASU 2016-08"), which clarifies the implementation guidance for principal versus agent considerations in ASU 2014-09. In April 2016, the FASB issued ASU No. 2016-10, "Revenue from Contracts with Customers (Topic 606) — Identifying Performance Obligations and Licensing" ("ASU 2016-10"), which amends the guidance in ASU 2014-09 related to identifying performance obligations and accounting for licenses of intellectual property. The Company must adopt ASU 2016-08 and ASU 2016-10 with ASU 2014-09. Entities are permitted to adopt the standards as early as the original public entity effective date of ASU 2014-09, and either full or modified retrospective application is required. The Company plans to adopt ASU 2014-09, ASU 2016-08, and ASU 2016-10 in the Company's fiscal year beginning October 1, 2019. The Company has not yet selected a transition method and is currently evaluating the impact of adopting this new accounting guidance and, therefore, cannot reasonably estimate the impact that the adoption of the above standards will have on its financial statements.
In February 2016, the FASB issued ASU No. 2016-02, "Leases (Topic 842)" ("ASU 2016-02"). ASU 2016-02 aims to increase transparency and comparability across organizations by requiring lease assets and lease liabilities to be recognized on the balance sheet as well as key information to be disclosed regarding lease arrangements. ASU 2016-02 is effective for annual reporting periods beginning after December 15, 2018, and interim periods within those fiscal years. Entities are permitted to adopt the standard early, and a modified retrospective application is required. The Company is currently evaluating the impact of adopting this new accounting guidance and, therefore, cannot reasonably estimate the impact that the adoption of this standard will have on its financial statements.
In August 2016, the FASB issued ASU No. 2016-15, "Statement of Cash Flows (Topic 230): Classification of Certain Cash Receipts and Cash Payments" ("ASU 2016-15"). ASU 2016-15 aims to reduce diversity in practice in how certain transactions are classified in the statement of cash flows. ASU 2016-15 is effective for annual reporting periods beginning after December 15, 2017 and interim periods within those fiscal years. Entities are permitted to adopt the standard early in any interim or annual period, and a retrospective application is required. The Company is currently evaluating the impact of adopting this new accounting guidance and, therefore, cannot reasonably estimate the impact that the adoption of this standard will have on its financial statements.
In January 2017, the FASB issued ASU No. 2017-04, "Intangibles - Goodwill and Other (Topic 350): Simplifying the Test for Goodwill Impairment" ("ASU 2017-04"). ASU 2017-04 removes Step 2 of the goodwill impairment test, which requires a hypothetical purchase price allocation. A goodwill impairment will now be the amount by which a reporting unit’s carrying value exceeds its fair value. ASU 2017-04 is effective for annual or any interim goodwill impairment tests in fiscal years beginning after December 15, 2019. Entities are permitted to adopt the standard early for interim or annual goodwill impairment tests performed on testing dates after January 1, 2017. The Company plans to early adopt this guidance during the fourth quarter of fiscal 2017 in conjunction with its annual goodwill impairment test. The Company does not expect any impact on its results of operations, cash flows, or financial position.

As of June 30, 2017, there were no other recently-issued accounting standards that may have a material impact on the Company’s financial position, results of operations, or cash flows upon their adoption.
 
Note 2. Revision of Previously Issued Financial Statements

In fiscal 2016, the Company engaged in a review of the accounting treatment of leases. As part of this review, the Company assessed its historical application of Accounting Standards Codification 840, "Leases," ("ASC 840") regarding lessee involvement in the construction of leased assets and identified corrections to be made in its accounting for these leases. In a number of its leases, the Company made payments for certain structural components included in the lessor's construction of the leased assets, which resulted in the Company being deemed the owner of the leased assets for accounting purposes. As a result, regardless of the significance of the payments, ASC 840 defines those payments as automatic indicators of ownership and requires the Company to capitalize the lessor's total project cost on the balance sheet with a corresponding financing obligation. In these situations, the Company had not historically accounted for the total project costs of the lessor as owned assets. Additionally, upon completion of the lessor's project, the Company must perform a sale-leaseback analysis pursuant to ASC 840 to determine if it can derecognize these assets and the related financing obligations from its consolidated balance sheet. In a substantial number of its leases, due to many of the same factors that require it to account for the total project costs as owned assets during the construction period (for example, the Company funding a portion of the construction costs), it was deemed to have "continuing involvement," which

7


precluded the Company from derecognizing these leased assets when construction was complete. In such cases, the leased assets and the related financing obligations remain on the consolidated balance sheet and are amortized over the life of the assets and the lease term, respectively.

The Company revised the prior year's financial statements. The corrections reduced diluted earnings per share by $0.01 in both the three and nine months ended June 30, 2016. The Company no longer reports rent expense for the leased facilities that are owned for accounting purposes. Instead, rental payments under the leases are recognized as a reduction of the financing obligation and as interest expense. Additionally, depreciation expense is recorded as construction assets are depreciated over their useful lives. These corrections had no impact on the net decrease in cash and cash equivalents in the nine months ended June 30, 2016.

The following illustrates the impact the aforementioned adjustments had on the Company's previously issued financial statements:

CONSOLIDATED STATEMENT OF OPERATIONS
 
 
Three months ended June 30, 2016
(in thousands, except per share data)
 
As Previously Reported
 
Adjustments
 
As Revised
Revenue
 
$
36,881,680

 
$

 
$
36,881,680

Cost of goods sold
 
35,773,817

 

 
35,773,817

Gross profit
 
1,107,863

 

 
1,107,863

Operating expenses:
 
 

 


 
 

Distribution, selling, and administrative
 
520,032

 
(3,594
)
 
516,438

Depreciation
 
52,419

 
1,581

 
54,000

Amortization
 
40,268

 

 
40,268

Warrants
 
(83,704
)
 

 
(83,704
)
Employee severance, litigation, and other
 
52,234

 

 
52,234

Operating income
 
526,614

 
2,013

 
528,627

Other income
 
(2,158
)
 

 
(2,158
)
Interest expense, net
 
32,115

 
3,038

 
35,153

Income before income taxes
 
496,657

 
(1,025
)
 
495,632

Income tax expense
 
146,854

 
(377
)
 
146,477

Net income
 
$
349,803

 
$
(648
)
 
$
349,155

 
 
 
 
 
 
 
Earnings per share:
 
 

 
 
 
 

Basic
 
$
1.62

 
$

 
$
1.62

Diluted
 
$
1.56

 
$
(0.01
)
 
$
1.55

 
 
 
 
 
 
 
Weighted average common shares outstanding:
 
 

 
 
 
 

Basic
 
215,688

 

 
215,688

Diluted
 
224,802

 

 
224,802

















8



CONSOLIDATED STATEMENT OF OPERATIONS
 
 
Nine months ended June 30, 2016
(in thousands, except per share data)
 
As Previously Reported
 
Adjustments
 
As Revised
Revenue
 
$
109,289,083

 
$

 
$
109,289,083

Cost of goods sold
 
106,141,012

 

 
106,141,012

Gross profit
 
3,148,071

 

 
3,148,071

Operating expenses:
 

 


 

Distribution, selling, and administrative
 
1,571,088

 
(10,107
)
 
1,560,981

Depreciation
 
153,232

 
4,629

 
157,861

Amortization
 
112,205

 

 
112,205

Warrants
 
(120,275
)
 

 
(120,275
)
Employee severance, litigation, and other
 
88,719

 

 
88,719

Pension settlement
 
47,607

 

 
47,607

Operating income
 
1,295,495

 
5,478

 
1,300,973

Other income
 
(3,224
)
 

 
(3,224
)
Interest expense, net
 
96,107

 
8,753

 
104,860

Income before income taxes
 
1,202,612

 
(3,275
)
 
1,199,337

Income tax benefit
 
(81,703
)
 
(1,204
)
 
(82,907
)
Net income
 
$
1,284,315

 
$
(2,071
)
 
$
1,282,244

 
 
 
 
 
 
 
Earnings per share:
 
 

 
 
 
 

Basic
 
$
6.12

 
$
(0.01
)
 
$
6.11

Diluted
 
$
5.69

 
$
(0.01
)
 
$
5.68

 
 
 
 
 
 
 
Weighted average common shares outstanding:
 
 

 
 
 
 

Basic
 
209,898

 

 
209,898

Diluted
 
225,646

 

 
225,646





























9



CONSOLIDATED STATEMENTS OF COMPREHENSIVE INCOME
 
 
Three months ended June 30, 2016
(in thousands)
 
As Previously Reported
 
Adjustments
 
As Revised
Net income
 
$
349,803

 
$
(648
)
 
$
349,155

Other comprehensive loss:
 
 
 
 

 
 
Net change in foreign currency translation adjustments
 
(8,911
)
 

 
(8,911
)
Other
 
117

 

 
117

Total other comprehensive loss
 
(8,794
)
 

 
(8,794
)
Total comprehensive income
 
$
341,009

 
$
(648
)
 
$
340,361


 
 
Nine months ended June 30, 2016
(in thousands)
 
As Previously Reported
 
Adjustments
 
As Revised
Net income
 
$
1,284,315

 
$
(2,071
)
 
$
1,282,244

Other comprehensive income:
 
 
 
 

 
 
Net change in foreign currency translation adjustments
 
(5,434
)
 

 
(5,434
)
Pension plan adjustment, net of tax of $19,054
 
31,538

 

 
31,538

Other
 
(749
)
 

 
(749
)
Total other comprehensive income
 
25,355

 

 
25,355

Total comprehensive income
 
$
1,309,670

 
$
(2,071
)
 
$
1,307,599




































10



CONSOLIDATED STATEMENT OF CASH FLOWS
 
 
Nine months ended June 30, 2016
(in thousands)
 
As Previously Reported
 
Adjustments
 
As Revised
OPERATING ACTIVITIES
 
 

 
 

 
 

Net income
 
$
1,284,315

 
$
(2,071
)
 
$
1,282,244

Adjustments to reconcile net income to net cash provided by operating    activities:
 


 


 


Depreciation, including amounts charged to cost of goods sold
 
167,124

 
4,629

 
171,753

Amortization, including amounts charged to interest expense
 
116,931

 
30

 
116,961

Provision for doubtful accounts
 
11,310

 

 
11,310

Benefit for deferred income taxes
 
(219,535
)
 
(1,204
)
 
(220,739
)
Warrants income
 
(120,275
)
 

 
(120,275
)
Share-based compensation
 
56,561

 

 
56,561

LIFO expense 1
 
274,305

 

 
274,305

Pension settlement
 
47,607

 

 
47,607

Other
 
(6,446
)
 

 
(6,446
)
Changes in operating assets and liabilities, excluding the effects of    acquisitions:
 
 
 
 
 
 
Accounts receivable
 
(705,462
)
 

 
(705,462
)
Merchandise inventories 1
 
(949,887
)
 

 
(949,887
)
Prepaid expenses and other assets
 
35,270

 

 
35,270

Accounts payable
 
1,776,565

 

 
1,776,565

Accrued expenses, income taxes, and other liabilities
 
53,575

 
634

 
54,209

NET CASH PROVIDED BY OPERATING ACTIVITIES
 
1,821,958

 
2,018

 
1,823,976

INVESTING ACTIVITIES
 
 

 
 

 
 

Capital expenditures
 
(310,178
)
 

 
(310,178
)
Cost of acquired companies, net of cash acquired
 
(2,731,356
)
 

 
(2,731,356
)
Cost of equity investments
 
(19,034
)
 

 
(19,034
)
Proceeds from sales of investment securities available-for-sale
 
101,829

 

 
101,829

Purchases of investment securities available-for-sale
 
(41,136
)
 

 
(41,136
)
Other
 
(21,186
)
 

 
(21,186
)
NET CASH USED IN INVESTING ACTIVITIES
 
(3,021,061
)
 

 
(3,021,061
)
FINANCING ACTIVITIES
 
 

 
 

 
 

Term loan borrowings
 
1,000,000

 

 
1,000,000

Term loan repayments
 
(600,000
)
 

 
(600,000
)
Borrowings under revolving and securitization credit facilities
 
8,788,432

 

 
8,788,432

Repayments under revolving and securitization credit facilities
 
(8,273,610
)
 

 
(8,273,610
)
Purchases of common stock
 
(1,023,149
)
 

 
(1,023,149
)
Exercises of warrants
 
1,168,891

 

 
1,168,891

Exercises of stock options, including excess tax benefits of $21,853
 
73,356

 

 
73,356

Cash dividends on common stock
 
(215,070
)
 

 
(215,070
)
Tax withholdings related to restricted share vesting
 
(18,935
)
 

 
(18,935
)
Other
 
(3,052
)
 
(2,018
)
 
(5,070
)
NET CASH PROVIDED BY FINANCING ACTIVITIES
 
896,863

 
(2,018
)
 
894,845

DECREASE IN CASH AND CASH EQUIVALENTS
 
(302,240
)
 

 
(302,240
)
Cash and cash equivalents at beginning of period
 
2,167,442

 

 
2,167,442

CASH AND CASH EQUIVALENTS AT END OF PERIOD
 
$
1,865,202

 
$

 
$
1,865,202


1 Amounts as previously reported have been revised to report LIFO Expense separately from the change in Merchandise Inventories.






11


Note 3.  Income Taxes
 
The Company files income tax returns in U.S. federal and state jurisdictions as well as various foreign jurisdictions. As of June 30, 2017, the Company had unrecognized tax benefits, defined as the aggregate tax effect of differences between tax return positions and the benefits recognized in the Company’s financial statements, of $100.8 million ($72.0 million, net of federal benefit). If recognized, these tax benefits would reduce income tax expense and the effective tax rate.  Included in this amount is $15.1 million of interest and penalties, which the Company records in income tax expense. During the nine months ended June 30, 2017, unrecognized tax benefits increased by $12.6 million. Over the next 12 months, it is reasonably possible that state tax audit resolutions and the expiration of statutes of limitations could result in a reduction of unrecognized tax benefits by approximately $4.8 million.

The Company's effective tax rates were 62.2% and 34.9% in the three and nine months ended June 30, 2017, respectively. The Company's effective tax rates were 29.6% and (6.9)% in the three and nine months ended June 30, 2016, respectively. The effective tax rates in the three and nine months ended June 30, 2017 were negatively impacted by non-deductible legal settlement charges (see Note 9), offset in part by certain discrete items, the growth of the Company's international businesses in Switzerland and Ireland that have significantly lower income tax rates, and the benefit from stock option exercises and restricted stock vesting. Prior to fiscal 2017, tax benefits resulting from share-based compensation were recorded as adjustments to Additional Paid-In Capital within Stockholders' Equity (see Note 1). The effective tax rate in the three months ended June 30, 2016 was favorably impacted primarily by the Company's international businesses that have lower income tax rates. The effective tax rate in the nine months ended June 30, 2016 primarily benefited from the receipt of an Internal Revenue Service private letter ruling that entitled the Company to an income tax deduction equal to the fair value of the Warrants on the dates of exercise.
 
Note 4.  Goodwill and Other Intangible Assets
 
Following is a summary of the changes in the carrying value of goodwill, by reportable segment, for the nine months ended June 30, 2017:
(in thousands)
 
Pharmaceutical
Distribution
Services
 
Other
 
Total
Goodwill at September 30, 2016
 
$
4,264,485

 
$
1,727,012

 
$
5,991,497

Goodwill recognized in connection with acquisitions
 

 
54,136

 
54,136

Goodwill disposed in connection with divestiture
 

 
(3,564
)
 
(3,564
)
Foreign currency translation
 

 
483

 
483

Goodwill at June 30, 2017
 
$
4,264,485

 
$
1,778,067

 
$
6,042,552


Following is a summary of other intangible assets:
 
 
June 30, 2017
 
September 30, 2016
(in thousands)
 
Gross
Carrying
Amount
 
Accumulated
Amortization
 
Net
Carrying
Amount
 
Gross
Carrying
Amount
 
Accumulated
Amortization
 
Net
Carrying
Amount
Indefinite-lived trade names
 
$
685,016

 
$

 
$
685,016

 
$
684,991

 
$

 
$
684,991

Finite-lived:
 
 
 
 
 
 
 
 
 
 
 
 
   Customer relationships
 
2,326,034

 
(374,591
)
 
1,951,443

 
2,322,404

 
(273,638
)
 
2,048,766

   Trade names and other
 
326,397

 
(91,430
)
 
234,967

 
307,234

 
(73,142
)
 
234,092

Total other intangible assets
 
$
3,337,447

 
$
(466,021
)
 
$
2,871,426

 
$
3,314,629

 
$
(346,780
)
 
$
2,967,849

 
Amortization expense for finite-lived intangible assets was $40.0 million and $40.3 million in the three months ended June 30, 2017 and 2016, respectively. Amortization expense for finite-lived intangible assets was $120.2 million and $112.2 million in the nine months ended June 30, 2017 and 2016, respectively. Amortization expense for finite-lived intangible assets is estimated to be $161.1 million in fiscal 2017, $161.3 million in fiscal 2018, $156.6 million in fiscal 2019, $152.0 million in fiscal 2020, $150.7 million in fiscal 2021, and $1,525.3 million thereafter.
 

12


Note 5.  Debt
 
Debt consisted of the following:
(in thousands)
 
June 30,
2017
 
September 30,
2016
Revolving credit note
 
$

 
$

Receivables securitization facility due 2019
 
500,000

 
500,000

Term loans due in 2020
 
547,659

 
697,055

Multi-currency revolving credit facility due 2021
 

 

Overdraft facility due 2021
 
4,119

 
11,275

$600,000, 1.15% senior notes due 2017
 

 
598,935

$400,000, 4.875% senior notes due 2019
 
398,217

 
397,669

$500,000, 3.50% senior notes due 2021
 
497,748

 
497,361

$500,000, 3.40% senior notes due 2024
 
496,643

 
496,276

$500,000, 3.25% senior notes due 2025
 
494,779

 
494,266

$500,000, 4.25% senior notes due 2045
 
494,028

 
493,866

Total debt
 
3,433,193

 
4,186,703

Less current portion
 
4,119

 
610,210

Total, net of current portion
 
$
3,429,074

 
$
3,576,493

 
In May 2017, the Company repaid the $600 million of 1.15% senior notes that became due.

The Company has a $1.4 billion multi-currency senior unsecured revolving credit facility ("Multi-Currency Revolving Credit Facility"), which expires in November 2021, with a syndicate of lenders. Interest on borrowings under the Multi-Currency Revolving Credit Facility accrues at specified rates based on the Company’s debt rating and ranges from 70 basis points to 110 basis points over CDOR/LIBOR/EURIBOR/Bankers Acceptance Stamping Fee, as applicable (91 basis points over CDOR/LIBOR/EURIBOR/Bankers Acceptance Stamping Fee at June 30, 2017) and from 0 basis points to 10 basis points over the alternate base rate and Canadian prime rate, as applicable. The Company pays facility fees to maintain the availability under the Multi-Currency Revolving Credit Facility at specified rates based on its debt rating, ranging from 5 basis points to 15 basis points, annually, of the total commitment (9 basis points at June 30, 2017). The Company may choose to repay or reduce its commitments under the Multi-Currency Revolving Credit Facility at any time. The Multi-Currency Revolving Credit Facility contains covenants, including compliance with a financial leverage ratio test, as well as others that impose limitations on, among other things, indebtedness of subsidiaries and asset sales, with which the Company was compliant as of June 30, 2017.
 
The Company has a commercial paper program whereby it may from time to time issue short-term promissory notes in an aggregate amount of up to $1.4 billion at any one time. Amounts available under the program may be borrowed, repaid, and re-borrowed from time to time. The maturities on the notes will vary, but may not exceed 365 days from the date of issuance. The notes will bear interest, if interest bearing, or will be sold at a discount from their face amounts. The commercial paper program does not increase the Company’s borrowing capacity as it is fully backed by the Company’s Multi-Currency Revolving Credit Facility. There were no borrowings outstanding under the commercial paper program as of June 30, 2017.
 
The Company has a $1,450 million receivables securitization facility ("Receivables Securitization Facility"), which expires in November 2019. The Company has available to it an accordion feature whereby the commitment on the Receivables Securitization Facility may be increased by up to $250 million, subject to lender approval, for seasonal needs during the December and March quarters. Interest rates are based on prevailing market rates for short-term commercial paper or LIBOR, plus a program fee. The Company pays a customary unused fee at prevailing market rates, annually, to maintain the availability under the Receivables Securitization Facility. The Receivables Securitization Facility contains similar covenants to the Multi-Currency Revolving Credit Facility, with which the Company was compliant as of June 30, 2017.
 
The Company has an uncommitted, unsecured line of credit available to it pursuant to a revolving credit note ("Revolving Credit Note"). The Revolving Credit Note provides the Company with the ability to request short-term unsecured revolving credit loans from time to time in a principal amount not to exceed $75 million. The Revolving Credit Note may be decreased or terminated by the bank or the Company at any time without prior notice. The Company also has a £30 million uncommitted U.K. overdraft facility ("Overdraft Facility"), which expires in February 2021, to fund short-term normal trading cycle fluctuations related to its MWI Animal Health ("MWI") business.
 

13


In February 2015, the Company entered into a $1.0 billion variable-rate term loan ("February 2015 Term Loan"), which matures in 2020. Through June 30, 2017, the Company elected to make principal payments, prior to the scheduled repayment dates, of $775 million on the February 2015 Term Loan, and as a result, the Company’s next required principal payment is due upon maturity. The February 2015 Term Loan bears interest at a rate equal either to a base rate plus a margin, or LIBOR, plus a margin. The margin is based on the public debt ratings of the Company and ranges from 75 basis points to 125 basis points over LIBOR (100 basis points at June 30, 2017) and 0 basis points to 25 basis points over a base rate. The February 2015 Term Loan contains similar covenants to the Multi-Currency Revolving Credit Facility, with which the Company was compliant as of June 30, 2017.
 
In November 2015, the Company entered into a $1.0 billion variable-rate term loan ("November 2015 Term Loan"), which matures in 2020. In March 2016, the Company made a scheduled principal payment of $25 million. Additionally, through June 30, 2017, the Company elected to make principal payments, prior to the scheduled repayment date, of $650 million on the November 2015 Term Loan, and as a result, the Company's next required principal payment is due upon maturity. The November 2015 Term Loan bears interest at a rate equal either to a base rate, plus a margin, or LIBOR, plus a margin. The margin is based on the public debt ratings of the Company and ranges from 75 basis points to 125 basis points over LIBOR (100 basis points at June 30, 2017) and 0 basis points to 25 basis points over a base rate. The November 2015 Term Loan contains similar covenants to the Multi-Currency Revolving Credit Facility, with which the Company was compliant as of June 30, 2017.
 
Note 6.  Stockholders’ Equity and Earnings per Share
 
In November 2016, the Company’s board of directors increased the quarterly cash dividend by 7% from $0.340 per share to $0.365 per share.
 
In May 2016, the Company's board of directors authorized a share repurchase program that, together with availability remaining under the previously approved August 2013 share repurchase program, permitted the Company to purchase up to $750 million of its outstanding shares of common stock, subject to market conditions. During the three months ended December 31, 2016, the Company purchased 2.1 million shares of its common stock (includes 0.5 million shares of common stock received as part of the settlement of the September 2016 accelerated share repurchase transaction) for a total of $118.8 million to complete its authorization under this program.

In November 2016, the Company's board of directors authorized a new share repurchase program allowing the Company to purchase up to $1.0 billion of its outstanding shares of common stock, subject to market conditions. During the nine months ended June 30, 2017, the Company purchased 1.4 million shares of its common stock for a total of $111.1 million. As of June 30, 2017, the Company had $888.9 million of availability remaining under the November 2016 share repurchase program.
 
Basic earnings per share is computed on the basis of the weighted average number of shares of common stock outstanding during the periods presented. Diluted earnings per share is computed on the basis of the weighted average number of shares of common stock outstanding during the periods presented, plus the dilutive effect of stock options, restricted stock, restricted stock units, and Warrants.
 
 
Three months ended
June 30,
 
Nine months ended
June 30,
(in thousands)
 
2017
 
2016
 
2017
 
2016
Weighted average common shares outstanding - basic
 
218,676

 
215,688

 
218,336

 
209,898

Dilutive effect of stock options, restricted stock, and restricted stock units
 
3,197

 
3,042

 
3,362

 
3,440

Dilutive effect of Warrants
 

 
6,072

 

 
12,308

Weighted average common shares outstanding - diluted
 
221,873


224,802


221,698


225,646

 
The potentially dilutive stock options, restricted stock, and restricted stock units that were antidilutive for the three and nine months ended June 30, 2017 were 3.7 million and 4.3 million, respectively. The potentially dilutive stock options, restricted stock, restricted stock units, and Warrants that were antidilutive for the three and nine months ended June 30, 2016 were 4.1 million and 2.6 million, respectively.
 

14


Note 7. Related Party Transactions
 
Walgreens Boots Alliance, Inc. ("WBA") owns more than 10% of the Company’s outstanding common stock and is, therefore, considered a related party. The Company operates under various agreements and arrangements with WBA, including a pharmaceutical distribution agreement, pursuant to which the Company distributes branded and generic pharmaceutical products to WBA, and an agreement that provides the Company the ability to access generics and related pharmaceutical products through a global sourcing arrangement with Walgreens Boots Alliance Development GmbH. Both of these agreements expire in 2026.
 
Revenue from the various agreements and arrangements with WBA was $11.2 billion and $33.4 billion in the three and nine months ended June 30, 2017, respectively. Revenue from the various agreements and arrangements with WBA was $10.8 billion and $32.5 billion in the three and nine months ended June 30, 2016, respectively. The Company’s receivable from WBA (after incentives owed to it) was $5.0 billion and $4.0 billion at June 30, 2017 and September 30, 2016, respectively.
 
Note 8. Employee Severance, Litigation, and Other

The following table illustrates the charges by the Company relating to employee severance, litigation, and other for the three and nine months ended June 30, 2017 and 2016:
 
 
Three months ended
June 30,
 
Nine months ended
June 30,
(in thousands)
 
2017
 
2016
 
2017
 
2016
Litigation settlements
 
$
273,400

 
$

 
$
289,400

 
$

Employee severance and other costs
 
9,584

 
34,554

 
21,767

 
40,247

Deal-related transaction costs
 
1,533

 
531

 
6,350

 
18,323

Transfer of surplus assets from a settled salaried defined    benefit pension plan to a defined contribution 401(k)    plan
 

 
17,149

 

 
17,149

Customer contract dispute settlements
 

 

 

 
13,000

    Total employee severance, litigation, and other
 
$
284,517

 
$
52,234

 
$
317,517

 
$
88,719


For the three months ended June 30, 2017, the Company incurred $273.4 million of charges for litigation settlements (see Note 9), $9.6 million of costs primarily related to facility closures and certain acquisition-related integration costs, and $1.5 million of deal-related transaction costs. For the nine months ended June 30, 2017, the Company incurred $289.4 million of charges for litigation settlements, $21.8 million of costs primarily related to facility closures and certain acquisition-related integration costs, and $6.4 million of deal-related transaction costs. For the three months ended June 30, 2016, the Company incurred $34.6 million of employee severance and other costs, a $17.1 million charge related to the transfer of surplus assets from the Company's settled salaried defined benefit pension plan to its defined contribution 401(k) plan, and $0.5 million of deal-related transaction costs. For the nine months ended June 30, 2016, the Company incurred $40.2 million of employee severance and other costs, $18.3 million of deal-related transaction costs (primarily related to professional fees with respect to the PharMEDium acquisition), a $17.1 million charge related to the transfer of surplus assets from the Company's settled salaried defined benefit pension plan to its defined contribution 401(k) plan, and $13.0 million of costs related to customer contract extensions (primarily related to the settlement of certain disputed items).

Employees receive their severance benefits over a period of time, generally not in excess of 12 months, or in the form of a lump-sum payment.

Note 9. Legal Matters and Contingencies
In the ordinary course of its business, the Company becomes involved in lawsuits, administrative proceedings, government subpoenas, and government investigations, including antitrust, commercial, environmental, product liability, intellectual property, regulatory, employment discrimination, and other matters. Significant damages or penalties may be sought from the Company in some matters, and some matters may require years for the Company to resolve. The Company records a reserve for these matters when it is both probable that a liability has been incurred and the amount of the loss can be reasonably estimated. With respect to the specific legal proceedings and claims described below, except as otherwise noted, the amount or range of possible losses is not reasonably estimable. There can be no assurance that the settlement, resolution, or other outcome of one or more matters, including the matters set forth below, during any subsequent reporting period will not have a material adverse effect on the Company's results of operations or cash flows for that period or on the Company's financial condition.

15


 
Government Enforcement and Related Litigation Matters
 
The Company is involved in government investigations and litigation arising from the marketing, promotion, sale, and dispensing of pharmaceutical products in the United States. Some of these investigations originate through what are known as qui tam complaints of the Federal False Claims Act. The qui tam provisions of the Federal Civil False Claims Act and various state and local civil False Claims Acts permit a private person, known as a "relator" or whistleblower, to file civil actions under these statutes on behalf of the federal, state, and local governments. Qui tam complaints are initially filed by the relator under seal (or on a confidential basis) and the filing of the complaint imposes obligations on government authorities to investigate the allegations in the complaint and to determine whether or not to intervene in the action. Qui tam complaints remain sealed until the court in which the case was filed orders otherwise.

Under the Federal False Claims Act, the government (or relators who pursue the claims without the participation of the government in the case) may seek to recover up to three times the amount of damages in addition to a civil penalty for each allegedly false claim submitted to the government for payment. Generally speaking, these cases take several years for the investigation to be completed and, ultimately, to be resolved (either through litigation or settlement) after the complaint is unsealed. In addition, some states have pursued investigations under state false claims statutes or consumer protection laws, either in conjunction with a government investigation or separately. There is often collateral litigation that arises from public disclosures of government investigations, including the filing of class action lawsuits by third party payors or by shareholders alleging violations of the securities laws.

The Federal Food, Drug, and Cosmetic Act ("FDCA") contains provisions relating to the sale and distribution of pharmaceutical products that are alleged to be adulterated or misbranded. The FDCA includes strict-liability criminal offenses that can be pursued by the government for violations of the FDCA and which can result in the imposition of substantial fines and penalties against corporations and individuals.

The Company has learned that there are filings in one or more federal district courts, including a qui tam complaint filed by one of its former employees, that are under seal and may involve allegations against the Company (and/or subsidiaries or businesses of the Company, including its group purchasing organization for oncologists and its oncology distribution business) relating to its distribution of certain pharmaceutical products to providers.

Subpoenas and Ongoing Investigations
 
From time to time, the Company receives subpoenas or requests for information from various government agencies relating to the Company's business or to the business of a customer, supplier, or other industry participant. The Company generally responds to such subpoenas and requests in a cooperative manner. These responses often require time and effort and can result in considerable costs being incurred by the Company. Most of these matters are resolved without incident; however, such subpoenas or requests can lead to the assertion of claims or the commencement of civil or criminal legal proceedings against the Company and other members of the health care industry, as well as to substantial settlements.
 
Since fiscal 2012, the Company and its subsidiary AmerisourceBergen Specialty Group ("ABSG") have been responding to subpoenas from the United States Attorney's Office for the Eastern District of New York ("USAO-EDNY") requesting production of documents and information relating to the pre-filled syringe program of ABSG’s subsidiary Medical Initiatives, Inc., ABSG's oncology distribution center, its group purchasing organization for oncologists, and intercompany transfers of certain oncology products. Medical Initiatives, Inc. voluntarily ceased operations in early 2014. The Company has produced documents and witnesses, and has engaged in ongoing dialogue with the USAO-EDNY, since 2012.
ABSG recently reached an agreement in principle with the USAO-EDNY which the Company understands will resolve the government’s criminal investigation in its entirety. The agreement in principle is subject to negotiation of final terms, approval by the parties and execution of definitive documents, and the approval of the Court. Under the terms of the agreement in principle, ABSG will pay $260.0 million and plead guilty to a strict liability misdemeanor offense under the FDCA in connection with the failure of Medical Initiatives, Inc. to duly register with the United States Food and Drug Administration, and the Company will enter into a Compliance Agreement with the United States Department of Justice. In connection with the agreement in principle, the Company recorded a litigation reserve of $260.0 million in Employee Severance, Litigation, and Other on the Company's Consolidated Statements of Operations for the three and nine months ended June 30, 2017.
The USAO-EDNY has also indicated that it intends to pursue alleged civil claims under the False Claims Act. Discussions with the USAO-EDNY to resolve such claims are ongoing, however there are significant disagreements between the parties and it remains unclear whether a settlement can be reached at this time or whether the matter will proceed to litigation. Should the

16


matter proceed to litigation, the Company intends to vigorously defend itself. Any settlement or other resolution of this civil matter could have an adverse effect on our business, results of operations, or cash flows. The Company is unable to reasonably estimate a range of loss, and no conclusion can be drawn at this time as to any likely outcome in this matter.
 
In fiscal 2012, the Company's subsidiary AmerisourceBergen Drug Corporation ("ABDC") received a subpoena from the United States Attorney's Office for the District of New Jersey ("USAO-NJ") in connection with a grand jury proceeding requesting documents concerning ABDC's program for controlling and monitoring diversion of controlled substances into channels other than for legitimate medical, scientific, and industrial purposes. ABDC also received a subpoena from the Drug Enforcement Administration ("DEA") in connection with the matter. Since fiscal 2012, ABDC has received and responded to a number of subpoenas from both the USAO-NJ and DEA requesting grand jury testimony and additional information related to electronically stored information, documents concerning specific customers' purchases of controlled substances, and DEA audits. In July 2017, the USAO-NJ and DEA served an administrative subpoena seeking records and requests relating to ABDC’s diversion control programs from 2013 to the present. The Company continues to engage in dialogue with the USAO-NJ, including discussions to attempt to reach a negotiated settlement. No conclusion can be drawn at this time as to any likely outcome in this matter.
 
Since fiscal 2013, the Company or ABDC has received subpoenas from the United States Attorney's Office for the District of Kansas and the United States Attorney's Office for the Northern District of Ohio in connection with grand jury proceedings requesting documents concerning ABDC's program for controlling and monitoring diversion of controlled substances into channels other than for legitimate medical, scientific and industrial purposes. As in the USAO-NJ matter described above, in addition to requesting information on ABDC's diversion control program generally, the subpoenas have also requested documents concerning specific customers' purchases of controlled substances. The Company has responded to the subpoenas and requests for information.
 
The Company’s subsidiary U.S. Bioservices Corporation ("US Bio") has reached an agreement in principle with the United States Attorney’s Office for the Southern District of New York ("USAO-SDNY") related to the previously disclosed matter involving the dispensing of one product and US Bio’s relationship with the manufacturer of that product. The Company understands that settlement pursuant to the agreement in principle will resolve the government’s investigation in its entirety. The agreement in principle is subject to negotiation of final terms, approval by the parties, and execution of definitive documents. Under the terms of the agreement in principle, this matter will be dismissed with prejudice pursuant to a settlement stipulation, upon entry by the Court, which will provide for the payment of $13.4 million and the express denial of the allegations and any wrongdoing. The Company recorded a litigation reserve of $13.4 million in Employee Severance, Litigation, and Other on the Company's Consolidated Statements of Operations for the three and nine months ended June 30, 2017.

In January 2017, US Bio received a subpoena for information from the USAO-EDNY relating to US Bio’s activities in connection with billing for products and making returns of potential overpayments to government payers. The Company is engaged in discussions with the USAO-EDNY and will be producing documents in response to the subpoena.

For those matters for which the Company has not recognized a liability, the Company cannot predict the outcome of ongoing investigations or their impact on the Company as uncertainty remains with regard to whether such matters will proceed to trial, whether settlements will be reached and the amount and terms of any such settlements. Outcomes may include settlements in significant amounts that are not currently estimable, limitations on the Company's conduct, the imposition of corporate integrity obligations and/or other civil and criminal penalties.

State Proceedings
 
In June 2012, the Attorney General of the State of West Virginia ("West Virginia AG") filed complaints, which were amended, in the Circuit Court of Boone County, West Virginia, against a number of pharmaceutical wholesale distributors, including the Company's subsidiary ABDC, alleging, among other claims, that the distributors failed to provide effective controls and procedures to guard against diversion of controlled substances for illegitimate purposes in West Virginia, acted negligently by distributing controlled substances to pharmacies that serve individuals who abuse controlled substances, and failed to report suspicious orders of uncontrolled substances in accordance with state regulations. The West Virginia AG was seeking monetary damages and injunctive and other equitable relief. This matter was dismissed with prejudice on January 9, 2017 pursuant to a settlement agreement that provided for the payment of $16.0 million and express denial of the allegations in the complaints and any wrongdoing. During the nine months ended June 30, 2017, the Company recognized the $16.0 million settlement in Employee Severance, Litigation, and Other on the Company's Consolidated Statements of Operations.

ABDC was sued in West Virginia state court by McDowell County, West Virginia on December 23, 2016, with an Amended Complaint filed on February 24, 2017, alleging, among other claims, negligence in the distribution of controlled substances, violation of the West Virginia Controlled Substances Act, and unjust enrichment. ABDC filed a notice of removal of this matter

17


on January 26, 2017 and a motion to dismiss the Amended Complaint with prejudice on March 17, 2017. The county’s motion to remand was denied, so the case remains pending in federal court in West Virginia. ABDC was sued in state court by the City of Huntington, West Virginia on January 20, 2017, with an Amended Complaint filed on January 26, 2017 but not served, asserting similar claims to the McDowell County action, including for negligence, violation of the West Virginia Controlled Substances Act, and unjust enrichment. ABDC filed a notice of removal of this matter on February 23, 2017 and a motion to dismiss on March 2, 2017. Four additional cities, Williamson, Gilbert, Kermit and Welch, and the County Commission for Lincoln County have filed suit against ABDC asserting similar claims in state court. Each of those cases was removed to federal court and the deadlines for filing responsive pleadings, including motions to dismiss, are stayed until after briefing of the expected motions to remand. Additionally, seven County Commissions (Boone, Cabell, Fayette, Kanawha, Logan, Wayne and Wyoming) have filed suit in federal court, each asserting a single claim for public nuisance. ABDC has filed a motion to dismiss each of those federal complaints. The motions to dismiss the seven federal complaints were argued on June 20, 2017, and no decision has yet been issued on those motions.

On April 24, 2017, a lawsuit was filed on behalf of the Cherokee Nation in the District Court for the Cherokee Nation against ABDC, other distributors, and pharmacies. This case alleges claims similar to those in the cases brought by certain counties and cities in West Virginia, including, among others, claims for violation of the Cherokee Nation Unfair and Deceptive Practices Act, nuisance, negligence/gross negligence and unjust enrichment. ABDC and its co-defendants filed a declaratory judgment action in the Northern District of Oklahoma seeking a judgment that the District Court for the Cherokee Nation lacks jurisdiction over the defendants and the claims. The defendants also filed a motion for preliminary injunction. The proceeding in the court of the Cherokee Nation is temporarily stayed pending the outcome of the preliminary injunction motion. The Cherokee Nation filed its response to the preliminary injunction motion on July 21, 2017.

On June 5, 2017, the City of Dayton, Ohio filed a lawsuit against distributors, manufacturers of controlled substances, and key opinion leaders alleged to have promoted the use of certain controlled substances. The complaint asserts claims of violation of the Ohio Consumer Sales Practices statute, violation of the Ohio Deceptive Trade Practices statute, public nuisance under both statutory and common law, fraud and unjust enrichment against all defendants. A separate single count of negligence has also been alleged against distributor defendants. ABDC has not yet been served with the complaint from the City of Dayton. On July 7, 2017, the manufacturer defendants filed a notice of removal which alleges that the distributor defendants, including ABDC, are dispensable parties subject to severance, or were fraudulently misjoined. On June 29, 2017, the City of Lorain, Ohio filed a similar lawsuit containing the same allegations and claims as the Dayton lawsuit. ABDC has not yet filed responsive pleadings in either matter, but anticipates filing Motions to Dismiss at the appropriate time.

On June 12, 2017, Nassau County, New York filed a lawsuit against distributors, manufacturers of controlled substances, and individuals. This lawsuit was filed by the same plaintiff’s counsel as the two Ohio cases and contains identical allegations and claims. ABDC has not filed a responsive pleading, but anticipates filing a motion to dismiss in advance of September 22, 2017, the date on which responsive pleadings are due.

Other entities, including additional attorney general’s offices, counties and cities in multiple states, have indicated their intent to sue. ABDC intends to vigorously defend itself against the pending and any threatened lawsuits. The Company is not in a position to assess the likely outcome or its exposure, if any, with respect to these matters.

Other Litigation
 
On September 10, 2014, PharMerica Corp., Pharmacy Corporation of America and Chem Rx Pharmacy Services, LLC (collectively, "PMC"), customers of ABDC until March 3, 2015, filed a complaint in Jefferson Circuit Court in Louisville, Kentucky against ABDC. The original complaint alleged that ABDC failed to pay in excess of $8 million in rebates pursuant to a prime vendor agreement between PMC and ABDC under which ABDC distributed pharmaceuticals and other products to PMC. PMC subsequently amended its complaint three times. PMC’s current complaint alleges unpaid-rebate claims in excess of $33 million and additional breaches and damages for unspecified amounts, which amounts may exceed $100 million.
ABDC answered all of the complaints, denied PMC’s allegations, and filed counterclaims alleging, among other things, that PMC failed to pay nearly $50 million in invoices related to pharmaceutical products it received from ABDC. On April 1, 2016, the Jefferson Circuit Court granted ABDC’s motion for partial summary judgment on one counterclaim and entered judgment in the amount of $48.6 million against PMC. On August 1, 2017, ABDC and PMC entered into an agreement in principle to resolve all claims in the litigation, including the pending judgment against PMC, for a one-time payment from PMC to ABDC of $3.1 million. As a result of this agreement in principle, the Company expects no impact to its consolidated results of operations. As part of the agreement in principle, the parties are requesting a stay of the judicial proceedings, which requires Court approval. The

18


settlement of the litigation will not be effective unless and until a newly formed entity controlled by KKR & Co. L.P., with Walgreens Boots Alliance, Inc. as a minority investor, completes its acquisition of PMC, which is expected to be completed in early 2018.

Note 10.  Litigation Settlements
 
Antitrust Settlements
 
Numerous class action lawsuits have been filed against certain brand pharmaceutical manufacturers alleging that the manufacturer, by itself or in concert with others, took improper actions to delay or prevent generic drugs from entering the market. The Company has not been named a plaintiff in any of these class actions, but has been a member of the direct purchasers’ class (i.e., those purchasers who purchase directly from these pharmaceutical manufacturers). None of the class actions have gone to trial, but some have settled in the past with the Company receiving proceeds from the settlement funds. The Company recognized no gains during the three months ended June 30, 2017 and recognized gains of $1.4 million during the nine months ended June 30, 2017 related to these class action lawsuits. During the three and nine months ended June 30, 2016, the Company recognized gains of $121.0 million and $133.8 million, respectively, related to these class action lawsuits. These gains, which are net of attorney fees and estimated payments due to other parties, were recorded as reductions to cost of goods sold in the Company’s consolidated statements of operations.
 
Note 11.  Fair Value of Financial Instruments
 
The recorded amounts of the Company’s cash and cash equivalents, accounts receivable, and accounts payable at June 30, 2017 and September 30, 2016 approximate fair value based upon the relatively short-term nature of these financial instruments. The Company had no investments in money market accounts as of June 30, 2017. Within cash and cash equivalents, the Company had $650.0 million of investments in money market accounts as of September 30, 2016. The fair value of the money market accounts was determined based on unadjusted quoted prices in active markets for identical assets, otherwise known as Level 1 inputs.
 
The Company had $100.4 million of investment securities available-for-sale, $95.7 million of which were within cash and cash equivalents, at June 30, 2017. The amortized cost of the investments was $100.4 million at June 30, 2017. The Company had $39.1 million of investment securities available-for-sale, $13.0 million of which were within cash and cash equivalents, at September 30, 2016. The amortized cost of the investments was $39.1 million at September 30, 2016. The fair value of the investments was based on inputs other than quoted market prices, otherwise known as Level 2 inputs. The investments held as of June 30, 2017 consisted of fixed-income securities maturing in July 2017. 
 
The recorded amount of long-term debt (see Note 5) and the corresponding fair value as of June 30, 2017 were $3,429.1 million and $3,521.2 million, respectively. The recorded amount of long-term debt and the corresponding fair value as of September 30, 2016 were $3,576.5 million and $3,750.9 million, respectively. The fair value of long-term debt was determined based on Level 2 inputs, as defined above.
 
Note 12.  Business Segment Information
 
The Company is organized based upon the products and services it provides to its customers. The Company’s operations are comprised of operating segments that are aggregated in the Pharmaceutical Distribution Services reportable segment and other operating segments that are not significant enough to require separate reportable segment disclosure, and, therefore, have been included in Other for the purpose of reportable segment presentation. The Pharmaceutical Distribution Services reportable segment consists of the ABDC and ABSG operating segments. Other consists of operating segments that focus on global commercialization services and animal health and includes AmerisourceBergen Consulting Services ("ABCS"), World Courier, and MWI Animal Health.

In June 2017, the Company announced its intention to combine the ABDC and ABSG operating segments into a single operating segment. The Company expects this combination to be substantially completed by September 30, 2017. Additionally, upon completion of this reorganization, the Company's non-title third party logistics business (which is currently included within the Pharmaceutical Distribution Services reportable segment) will be combined with other operating segments that comprise Other, while ABCS's distribution business (currently included in Other) will be included in the Pharmaceutical Distribution Services reportable segment. The Company does not expect these changes to have a material impact to its historical reportable segment operating results.

19


 
The following tables illustrate reportable segment information for the three and nine months ended June 30, 2017 and 2016:
 
 
Revenue
 
 
Three months ended
June 30,
 
Nine months ended
June 30,
(in thousands)
 
2017
 
2016
 
2017
 
2016
Pharmaceutical Distribution Services
 
$
37,032,709

 
$
35,373,725

 
$
109,127,631

 
$
104,734,137

Other
 
1,743,954

 
1,576,368

 
5,103,745

 
4,753,988

Intersegment eliminations
 
(69,519
)
 
(68,413
)
 
(207,565
)
 
(199,042
)
Revenue
 
$
38,707,144

 
$
36,881,680

 
$
114,023,811

 
$
109,289,083

 
Intersegment eliminations primarily represent the elimination of certain ABCS sales to the Pharmaceutical Distribution Services reportable segment.
 
 
Segment Operating Income
 
 
Three months ended
June 30,
 
Nine months ended
June 30,
(in thousands)
 
2017
 
2016
 
2017
 
2016
 
 
 
 
(As Revised)
 
 
 
(As Revised)
Pharmaceutical Distribution Services
 
$
376,632

 
$
412,731

 
$
1,232,899

 
$
1,294,150

Other
 
94,682

 
82,511

 
313,094

 
272,032

Intersegment eliminations
 
(198
)
 

 
$
(212
)
 
$

Total segment operating income
 
$
471,116

 
$
495,242

 
$
1,545,781

 
$
1,566,182

 
The following table reconciles total segment operating income to income before income taxes:
 
 
Income Before Income Taxes
 
 
Three months ended
June 30,
 
Nine months ended
June 30,
(in thousands)
 
2017
 
2016
 
2017
 
2016
 
 
 
 
(As Revised)
 
 
 
(As Revised)
Total segment operating income
 
$
471,116

 
$
495,242

 
$
1,545,781

 
$
1,566,182

Gain from antitrust litigation settlements
 

 
120,960

 
1,395

 
133,758

LIFO credit (expense)
 
24,723

 
(80,364
)
 
82,919

 
(274,305
)
Acquisition-related intangibles amortization
 
(40,946
)
 
(38,681
)
 
(117,234
)
 
(108,611
)
Warrants income
 

 
83,704

 

 
120,275

Employee severance, litigation, and other
 
(284,517
)
 
(52,234
)
 
(317,517
)
 
(88,719
)
Pension settlement
 

 

 

 
(47,607
)
Operating income
 
170,376

 
528,627

 
1,195,344

 
1,300,973

Other loss (income)
 
1,398

 
(2,158
)
 
(3,958
)
 
(3,224
)
Interest expense, net
 
35,603

 
35,153

 
109,874

 
104,860

Income before income taxes
 
$
133,375

 
$
495,632

 
$
1,089,428

 
$
1,199,337

 
Segment operating income is evaluated by the chief operating decision maker of the Company before gain from antitrust litigation settlements; LIFO credit (expense); acquisition-related intangibles amortization; Warrants income; employee severance, litigation, and other; pension settlement; other loss (income); and interest expense, net. All corporate office expenses are allocated to each operating segment.


20

Table of Contents

ITEM 2.   Management’s Discussion and Analysis of Financial Condition and Results of Operations
Overview
The following discussion should be read in conjunction with the Consolidated Financial Statements and notes thereto contained herein and in conjunction with the financial statements and related notes included in our Annual Report on Form 10-K for the fiscal year ended September 30, 2016.
We are one of the largest global pharmaceutical sourcing and distribution services companies, helping both healthcare providers and pharmaceutical and biotech manufacturers improve patient access to products and enhance patient care. We deliver innovative programs and services designed to increase the effectiveness and efficiency of the pharmaceutical supply chain in both human and animal health. We are organized based upon the products and services we provide to our customers. Our operations are comprised of operating segments that are aggregated in the Pharmaceutical Distribution Services reportable segment and other operating segments that are not significant enough to require separate reportable segment disclosure, and, therefore, have been included in Other for the purpose of our reportable segment presentation.
Pharmaceutical Distribution Services Segment
The Pharmaceutical Distribution Services reportable segment is comprised of two operating segments, which include the operations of AmerisourceBergen Drug Corporation ("ABDC") and AmerisourceBergen Specialty Group ("ABSG"). In June 2017, we announced our intention to combine the ABDC and ABSG operating segments into a single operating segment. We expect this combination to be substantially completed by September 30, 2017. Additionally, upon completion of this reorganization, our non-title third party logistics business (which is currently included within the Pharmaceutical Distribution Services reportable segment) will be combined with other operating segments that comprise Other, while the AmerisourceBergen Consulting Services’ distribution business (currently included in Other) will be included in our Pharmaceutical Distribution Services reportable segment. We do not expect these changes to have a material impact to our historical reportable segment operating results.
Servicing healthcare providers in the pharmaceutical supply channel, the Pharmaceutical Distribution Services segment's operations provide drug distribution and related services designed to reduce healthcare costs and improve patient outcomes.
The Pharmaceutical Distribution Services reportable segment distributes a comprehensive offering of brand-name, specialty brand-name and generic pharmaceuticals, over-the-counter healthcare products, home healthcare supplies and equipment, outsourced compounded sterile preparations, and related services to a wide variety of healthcare providers, including acute care hospitals and health systems, independent and chain retail pharmacies, mail order pharmacies, medical clinics, long-term care and alternate site pharmacies, and other customers. Through a number of operating businesses, the Pharmaceutical Distribution Services reportable segment provides pharmaceutical distribution (including plasma and other blood products, injectible pharmaceuticals, vaccines, and other specialty pharmaceutical products) and additional services to physicians who specialize in a variety of disease states, especially oncology, and to other healthcare providers, including hospitals and dialysis clinics. Additionally, the Pharmaceutical Distribution Services reportable segment provides third party logistics, outcomes research, and additional services for biotechnology and pharmaceutical manufacturers. The Pharmaceutical Distribution Services reportable segment also provides pharmacy management, staffing and additional consulting services, and supply management software to a variety of retail and institutional healthcare providers. Additionally, it delivers packaging solutions to institutional and retail healthcare providers.
Our use of the term "specialty" and "specialty pharmaceutical products" refers to drugs used to treat complex diseases, such as cancer, diabetes, and multiple sclerosis. Specialty pharmaceutical products are part of complex treatment regimens for serious conditions and diseases that generally require ongoing clinical monitoring. We believe the terms "specialty" and "specialty pharmaceutical products" are used consistently by industry participants and our competitors. However, we cannot be certain that other distributors of specialty products define these and other similar terms in exactly the same manner as we do.
Other
Other consists of operating segments that focus on global commercialization services and animal health and includes AmerisourceBergen Consulting Services ("ABCS"), World Courier, and MWI Animal Health ("MWI").
ABCS, through a number of operating businesses, provides a full suite of integrated manufacturer services that range from clinical trial support to product post-approval and commercialization support. World Courier, which operates in over 50 countries, is a leading global specialty transportation and logistics provider for the biopharmaceutical industry. MWI is a leading animal health distribution company in the United States and in the United Kingdom. MWI sells pharmaceuticals, vaccines, parasiticides, diagnostics, micro feed ingredients, and various other products to customers in both the companion animal and production animal markets. Additionally, MWI offers demand-creating sales force services to manufacturers.

    

21

Table of Contents

Executive Summary
 
This executive summary provides highlights from the results of operations that follow:
 
Revenue increased 4.9% and 4.3% from the prior year quarter and nine month period, respectively, as a result of increased sales to some of ABDC's larger customers and the strong revenue growth of certain business units within ABSG, offset in part by a decline in sales of products that treat Hepatitis C;

Total gross profit decreased 2.5% in the current year quarter primarily due to the decrease in gains from antitrust litigation settlements of $121.0 million and a decrease in gross profit in Pharmaceutical Distribution Services, offset in part by a reduction of last-in, first-out ("LIFO") expense, which was a credit of $24.7 million in the current year quarter, in comparison to an expense charge of $80.4 million in the prior year quarter and an increase in gross profit in Other. Total gross profit increased 7.2% in the current year nine month period primarily due to the reduction of LIFO expense, which was a credit of $82.9 million in the current year nine month period, in comparison to an expense charge of $274.3 million in the prior year nine month period and an increase in gross profit in Other, offset in part by a decrease in gains from antitrust litigation settlements of $132.4 million and a decrease in gross profit in Pharmaceutical Distribution Services. The LIFO credits in the current year quarter and nine month period were primarily driven by lower expected brand inflation and greater expected generic deflation for fiscal 2017 in comparison to those expectations at June 30, 2016 for the prior fiscal year;
Pharmaceutical Distribution Services gross profit decreased 4.4% and 2.7% from the prior year quarter and nine month period, respectively. Gross profit in the current year quarter was adversely impacted by the prior year contract renewal effective July 1, 2016 at less favorable terms with Kaiser Permanente ("Kaiser"), lower price appreciation, and a lower contribution from PharMEDium as it shipped fewer units while we increased our investment in quality control and quality assurance systems to enhance product quality and patient safety and to meet all of PharMEDium's commitments to the U.S. Food and Drug Administration ("FDA") pursuant to the new federal requirements for outsourcing facilities. Gross profit growth in the current year nine month period was adversely impacted by the prior year contract renewals at less favorable terms with a significant group purchasing organization ("GPO") customer and Kaiser, and lower price appreciation;
Distribution, selling, and administrative expenses increased slightly compared to the prior year quarter and nine month period. Distribution, selling, and administrative expenses as a percentage of revenue were 1.36% and 1.38% in the current year quarter and nine month period, respectively, and represent decreases of 4 basis points compared to the prior year quarter and 5 basis points compared to the prior year nine month period. The decreases in expense as a percentage of revenue in comparison to the prior year periods were primarily due to initiatives taken in second half of fiscal 2016 to improve operating efficiency across many of our businesses and certain administrative functions;
Total operating expenses increased $330.3 million and $331.5 million from the prior year quarter and nine month period, respectively, primarily due to litigation settlements of $273.4 million and $289.4 million recognized during the quarter and nine month period ended June 30, 2017, respectively (see Note 9 of the Notes to Consolidated Financial Statements);
Total segment operating income decreased by 4.9% and 1.3% compared to the prior year quarter and nine month period, respectively, primarily due to the decline in Pharmaceutical Distribution Services' operating income due to the gross profit factors noted above and was partially offset by increased contributions from our businesses in Other, and;
Our effective tax rates were 62.2% and 34.9% in the three and nine months ended June 30, 2017, respectively. Our effective tax rates were 29.6% and (6.9)% in the three and nine months ended June 30, 2016, respectively. Our effective tax rates in the three and nine months ended June 30, 2017 were negatively impacted by non-deductible legal settlement charges (see Note 9 of the Notes to Consolidated Financial Statements), offset in part by certain discrete items, the growth of our international businesses in Switzerland and Ireland that have significantly lower income tax rates, and the benefit from stock option exercises and restricted stock vesting. Prior to fiscal 2017, tax benefits resulting from share-based compensation were recorded as adjustments to Additional Paid-In Capital within Stockholders' Equity (see Note 1 of the Notes to Consolidated Financial Statements). Our effective tax rate in the three months ended June 30, 2016 was favorably impacted primarily by our international businesses that have lower income tax rates. Our effective tax rate in the nine months ended June 30, 2016 primarily benefited from the receipt of an Internal Revenue Service ("IRS") private letter ruling that entitled us to an income tax deduction equal to the fair value of the Warrants on the dates of exercise.

22

Table of Contents

Results of Operations
 
Revenue
 
 
Three months ended
June 30,
 
 
 
Nine months ended
June 30,
 
 
(dollars in thousands)
 
2017
 
2016
 
Change
 
2017
 
2016
 
Change
Pharmaceutical Distribution     Services
 
$
37,032,709

 
$
35,373,725

 
4.7%
 
$
109,127,631

 
$
104,734,137

 
4.2%
Other
 
1,743,954

 
1,576,368

 
10.6%
 
5,103,745

 
4,753,988

 
7.4%
Intersegment eliminations
 
(69,519
)
 
(68,413
)
 
1.6%
 
(207,565
)
 
(199,042
)
 
4.3%
Revenue
 
$
38,707,144

 
$
36,881,680

 
4.9%
 
$
114,023,811

 
$
109,289,083

 
4.3%
 
Revenue increased by 4.9% and 4.3% from the prior year quarter and nine month period, respectively. See discussions below under "Pharmaceutical Distribution Services Segment" and "Other" for commentary regarding our revenue growth.
 
We currently expect our revenue in fiscal 2017 to increase by approximately 5%. Our future revenue growth will continue to be affected by various factors such as industry growth trends, including drug utilization, the introduction of new innovative brand therapies (including biosimilars), the likely increase in the number of generic drugs that will be available over the next few years as a result of the expiration of certain drug patents held by brand-name pharmaceutical manufacturers and the rate of conversion from brand products to those generic drugs, price increases and price deflation, general economic conditions in the United States, competition within the industry, customer consolidation, changes in pharmaceutical manufacturer pricing and distribution policies and practices, increased downward pressure on government and other third party reimbursement rates to our customers, and changes in federal government rules and regulations.
 
Pharmaceutical Distribution Services Segment
 
The Pharmaceutical Distribution Services segment grew its revenue by 4.7% and 4.2% from the prior year quarter and nine month period, respectively. Intrasegment revenue between ABDC and ABSG has been eliminated in the presentation of total Pharmaceutical Distribution Services revenue. Intrasegment revenue primarily consisted of ABSG sales directly to ABDC customer sites or ABSG sales to ABDC facilities. Intrasegment revenue was $2.5 billion and $2.0 billion in the quarters ended June 30, 2017 and 2016, respectively, and $6.8 billion and $5.5 billion in the nine month periods ended June 30, 2017 and 2016, respectively.
 
ABDC’s revenue of $31.4 billion and $92.8 billion in the quarter and nine months ended June 30, 2017 increased 4.5% and 3.9% from the prior year quarter and nine month period (before intrasegment eliminations), respectively. The increases in ABDC’s revenue were primarily due to the growth of some of ABDC's larger customers and due to overall market growth within the retail customer segment, offset in part by a decline in sales of products that treat Hepatitis C.
 
ABSG’s revenue of $8.1 billion and $23.2 billion in the quarter and nine months ended June 30, 2017 increased 10.3% and 10.5%, respectively, from the prior year quarter and nine month periods (before intrasegment eliminations), respectively. The increases in ABSG’s revenue were primarily due to strong overall performance, especially in the sale of oncology products, and increased sales in our third party logistics business.
 
A number of our contracts with customers, including GPOs, are typically subject to expiration each year. We may lose a significant customer if any existing contract with such customer expires without being extended, renewed, or replaced. During the nine months ended June 30, 2017, no significant contracts expired. Over the next twelve months, there are no significant contracts scheduled to expire. Additionally, from time to time, other significant contracts may be renewed prior to their expiration dates. If those contracts are renewed at less favorable terms, they may also negatively impact our revenue, results of operations, and cash flows.

Other
 
Revenue in Other increased 10.6% and 7.4% from the prior year quarter and nine month period, respectively, primarily due to increased revenue from MWI due to strong growth in its companion animal business and ABCS due to its growth in manufacturer service programs.
 

23

Table of Contents

Gross Profit
 
 
Three months ended
June 30,
 
 
 
Nine months ended
June 30,
 
 
(dollars in thousands)
 
2017
 
2016
 
Change
 
2017
 
2016
 
Change
Pharmaceutical Distribution     Services
 
$
759,254

 
794,424

 
(4.4)%
 
2,383,346

 
2,448,601

 
(2.7)%
Other
 
296,096

 
272,843

 
8.5%
 
906,534

 
840,017

 
7.9%
Intersegment eliminations
 
(198
)
 

 
 
 
(212
)
 

 
 
Gain from antitrust litigation settlements
 

 
120,960

 
 
 
1,395

 
133,758

 
 
LIFO credit (expense)
 
24,723

 
(80,364
)
 
 
 
82,919

 
(274,305
)
 
 
Gross profit
 
$
1,079,875

 
$
1,107,863

 
(2.5)%
 
$
3,373,982

 
$
3,148,071

 
7.2%
 
Gross profit decreased 2.5%, or $28.0 million from the prior year quarter, and increased 7.2%, or $225.9 million, from the prior year nine month period. The decrease in gross profit from the prior year quarter was primarily due to the $121.0 million decrease in gains from antitrust litigation settlements and a decrease in gross profit in Pharmaceutical Distribution Services, offset in part by the decrease in LIFO expense of $105.1 million and an increase in gross profit in Other. The increase in gross profit from the prior year nine month period was primarily due to a decrease in LIFO expense of $357.2 million and an increase in gross profit in Other, offset in part by a decrease in gains from antitrust litigation settlements of $132.4 million and a decrease in gross profit in Pharmaceutical Distribution Services. The LIFO credits in the current year quarter and nine month period were primarily driven by lower expected brand inflation and greater expected generic deflation for fiscal 2017 in comparison to those expectations at June 30, 2016 for the prior fiscal year.

Our cost of goods sold for interim periods includes a LIFO provision that is based on our estimated annual LIFO provision. The annual LIFO provision, which we estimate on a quarterly basis, is affected by expected changes in inventory quantities, product mix, and manufacturer pricing practices, which may be impacted by market and other external influences, many of which are difficult to predict. The generic deflation rate used for estimating our LIFO provision is typically greater than our base generic deflation rate (currently at -7% to -9% for fiscal 2017) due to various factors, including but not limited to declining prices on new generic products and changes in generic volumes and/or mix of products. Changes to any of the above factors may have a material impact to our annual LIFO provision.
 
Pharmaceutical Distribution Services gross profit decreased 4.4%, or $35.2 million, and 2.7%, or $65.3 million, from the prior year quarter and nine month period, respectively. Gross profit in the current year quarter was adversely impacted by the prior year contract renewal effective July 1, 2016 at less favorable terms with Kaiser, lower price appreciation, and a lower contribution from PharMEDium as it shipped fewer units while we increased our investment in quality control and quality assurance systems to enhance product quality and patient safety and to meet all of PharMEDium's commitments to the FDA pursuant to the new federal requirements for outsourcing facilities. We expect a lower contribution from PharMEDium through the remainder of fiscal 2017 until the aforementioned procedures have been fully implemented. Gross profit in the current year nine month period was adversely impacted by prior year contract renewals at less favorable terms with a significant GPO customer and Kaiser and lower price appreciation. As a percentage of revenue, Pharmaceutical Distribution Services gross profit margin of 2.05% and 2.18% in the quarter and nine months ended June 30, 2017, respectively, decreased 20 basis points and 16 basis points from the prior year quarter and nine month period, respectively. The decrease from the prior year quarter and nine month period was primarily due to the above-mentioned contract renewals, lower price appreciation, and increased sales to some of our larger customers that typically have a lower gross profit margin.
 
Gross profit in Other increased 8.5%, or $23.3 million, and 7.9%, or $66.5 million, from the prior year quarter and nine month period, respectively. The increases from the prior year periods were primarily due to revenue growth of ABCS and MWI. As a percentage of revenue, gross profit margin in Other of 16.98% in the quarter ended June 30, 2017 decreased from 17.31% in the prior year quarter primarily due to lower gross profit margin at MWI. As a percentage of revenue, gross profit margin in Other of 17.76% in the nine months ended June 30, 2017 increased from 17.67% in the prior year nine month period.

We recognized no gains from antitrust litigation settlements with pharmaceutical manufacturers in the quarter ended June 30, 2017. Gains from antitrust litigation settlements with pharmaceutical manufacturers were $121.0 million in the quarter ended June 30, 2016. We recognized gains of $1.4 million and $133.8 million from antitrust litigation settlements with pharmaceutical manufacturers during the nine months ended June 30, 2017 and 2016, respectively. The gains were recorded as reductions to cost of goods sold.
 

24

Table of Contents

Operating Expenses
 
 
Three months ended
June 30,
 
 
 
Nine months ended
June 30,
 
 
(dollars in thousands)
 
2017
 
2016
 
Change
 
2017
 
2016
 
Change
 
 
 
 
(As Revised)
 
 
 
 
 
(As Revised)
 
 
Distribution, selling, and administrative
 
$
525,463

 
$
516,438

 
1.7%
 
$
1,567,853

 
$
1,560,981

 
0.4%
Depreciation and amortization
 
99,519

 
94,268

 
5.6%
 
293,268

 
270,066

 
8.6%
Warrants income
 

 
(83,704
)
 
 
 

 
(120,275
)
 
 
Employee severance, litigation, and other
 
284,517

 
52,234

 
 
 
317,517

 
88,719

 
 
Pension settlement charge
 

 

 
 
 

 
47,607

 
 
Total operating expenses
 
$
909,499

 
$
579,236

 
57.0%
 
$
2,178,638

 
$
1,847,098

 
17.9%
 
Distribution, selling, and administrative expenses increased 1.7%, or $9.0 million, and 0.4%, or $6.9 million, from the prior year quarter and nine month period, respectively. As a percentage of revenue, distribution, selling, and administrative expenses were 1.36% and 1.38% in the current year quarter and nine month period, respectively, and represent decreases of 4 basis points compared to the prior year quarter and 5 basis points compared to the prior year nine month period. The decreases in expense as a percentage of revenue in comparison to the prior year periods were primarily due to initiatives taken in the second half of fiscal 2016 to improve operating efficiency across many of our businesses and certain administrative functions.
 
Depreciation expense increased 10.1% and 9.6% from the prior year quarter and nine month period, respectively, due to an increase in the amount of property and equipment placed in service. Amortization expense decreased 0.6% from the prior year quarter and increased 7.1% from the prior year nine month period. The increase in amortization expense from the prior year nine month period was primarily due to the amortization of intangible assets originating from our November 6, 2015 acquisition of PharMEDium.
 
There was no Warrants expense or income in the current fiscal year periods as the Warrants were exercised in March 2016 and August 2016.
 
Employee severance, litigation, and other for the quarter ended June 30, 2017 included $273.4 million for litigation settlements (see Note 9 of the Notes to the Consolidated Financial Statements for further details), $9.6 million of costs primarily related to facility closures and certain acquisition-related integration costs, and $1.5 million of deal-related transaction costs. Employee severance, litigation, and other for the nine months ended June 30, 2017 included $289.4 million for litigation settlements, $21.8 million of costs primarily related to facility closures and certain acquisition-related integration costs, and $6.4 million of deal-related transaction costs. Employee severance, litigation, and other for the quarter ended June 30, 2016 included $34.6 million of employee severance and other costs, a $17.1 million charge related to the transfer of surplus assets from our settled salaried defined benefit pension plan to our defined contribution 401(k) plan, and $0.5 million of deal-related transaction costs. Employee severance, litigation, and other for the nine months ended June 30, 2016 included $40.2 million of employee severance and other costs, $18.3 million of deal-related transaction costs (primarily related to professional fees with respect to the PharMEDium acquisition), a $17.1 million charge related to the transfer of surplus assets from our settled salaried defined benefit pension plan to our defined contribution 401(k) plan, and $13.0 million of costs related to customer contract extensions (primarily related to the settlement of certain disputed items).
 

25

Table of Contents

Operating Income
 
 
Three months ended
June 30,
 
 
 
Nine months ended
June 30,
 
 
(dollars in thousands)
 
2017
 
2016
 
Change
 
2017
 
2016
 
Change
 
 
 
 
(As Revised)
 
 
 
 
 
(As Revised)
 
 
Pharmaceutical Distribution     Services
 
$
376,632

 
$
412,731

 
(8.7)%
 
$
1,232,899

 
$
1,294,150

 
(4.7)%
Other
 
94,682

 
82,511

 
14.8%
 
313,094

 
272,032

 
15.1%
Intersegment eliminations
 
(198
)
 

 
 
 
(212
)
 

 
 
Total segment operating income
 
471,116

 
495,242

 
(4.9)%
 
1,545,781

 
1,566,182

 
(1.3)%
 
 
 
 
 
 
 
 
 
 
 
 
 
Gain from antitrust litigation settlements